Redenlab supporting new randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia
Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia run by Professor David Coman & team from The University of Queensland.
Redenlab are providing resources for speech and swallowing testing across this 12 month trial.
Ataxia telangiectasia (A-T) is rare condition that affects the nervous system, the immune system, & many other parts of the body. Signs & symptoms of the condition usually begin in early childhood, often before age 5. The condition is typically characterized by cerebellar ataxia, oculomotor apraxia, telangiectasias, choreoathetosis (uncontrollable movements of the limbs), a weakened immune system with frequent infections, & an increased risk of cancers such as leukemia & lymphoma. A-T is caused by changes (mutations) in the ATM gene & is inherited in an autosomal recessive manner. Treatment is supportive & based on the signs & symptoms present in each person.